Marvin Gee | VP, Head of Research
3T Biosciences

Marvin Gee, VP, Head of Research, 3T Biosciences

Dr. Gee is Vice President, Head of Research at 3T Biosciences. He is co-founder of 3T Biosciences and an internationally recognized expert and pioneer in the field of pHLA targeting via T cell receptors and bispecific T cell engagers. Dr. Gee brings more than a decade of domain expertise across the intersections of T cell receptor biology, immunology, structural biology, protein engineering, bioinformatics, and machine learning. He received his PhD in Immunology, with a focus in Computational Immunology at Stanford University in the laboratory of K. Christopher Garcia. Dr. Gee received a BS from Caltech  where he worked in the laboratory of David Baltimore to engineer T cell receptors for adoptive T cell therapy. For his accomplishments, he has been recognized and featured in Forbes 30-under-30 in Healthcare and Endpoints 20-under-40 in Biopharma.

Appearances:



Festival of Biologics Day 1 @ 14:20

Pioneering immunotherapy with a first-in-class bispecific T cell engager against a novel pHLA target

T cells recognize intracellular targets presented by HLA to enable potent anti-tumor immune responses, and these targets can be leveraged to generate off-the-shelf therapeutics using T cell bispecific engagers to treat a broad patient population. We've developed 3T-TRACE to rapidly identify the antigens of orphan T cells from patient tumors and 3T-PRIME, a TCR mimetic platform to rapidly generate potent and specific binders for therapeutic development.

last published: 22/Nov/24 17:05 GMT

back to speakers